Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn&apos;s Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Inflammatory Bowel Disease

Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY Trial

J Crohns Colitis

Ma C, Feagan BG, Wang Z, Zou G, Smith MI, Shackelton LM, Sands BE, Panaccione R, D'Haens GR, Vermeire S, Jairath V

doi: 10.1093/ecco-jcc/jjae113

Inflammatory Bowel Disease

Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

J Crohns Colitis

Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M

doi: 10.1093/ecco-jcc/jjaf005

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Further Publications

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Gut

Adler J, Gadepalli S, Rahman M, Kim S

doi: 10.1136/gutjnl-2024-333280

Inflammatory Bowel Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Gastroenterology

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G

doi: 10.1053/j.gastro.2025.02.033

Inflammatory Bowel Disease

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Inflamm Bowel Dis

Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ

doi: 10.1093/ibd/izaf036

Inflammatory Bowel Disease

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Lancet Gastroenterol Hepatol

Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S

doi: 10.1016/S2468-1253(25)00017-2

Inflammatory Bowel Disease

Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis

United European Gastroenterol J

Taxonera C, García-Brenes MA, Olivares D, López-García ON, Zapater R, Alba C

doi: 10.1002/ueg2.12673

Inflammatory Bowel Disease

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Gastroenterology

Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V

doi: 10.1053/j.gastro.2024.10.009

Related content

Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY Trial

Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis